Welcome to our dedicated page for Viatris news (Ticker: VTRS), a resource for investors and traders seeking the latest updates and insights on Viatris stock.
Viatris Inc. reports developments for a global healthcare company with a portfolio spanning generics, established brands and innovative medicines. News commonly covers quarterly results, guidance, cash deployment, dividends, capital allocation and management changes, alongside product launches and pipeline updates across major therapeutic areas.
Company updates also include scientific presentations and regulatory actions tied to specific medicines and candidates, including Effexor in Japan, ophthalmology programs such as phentolamine ophthalmic solution and RYZUMVI, and an investigational low-dose estrogen combined hormonal contraceptive weekly patch. Viatris was formed through the combination of Mylan and Pfizer's Upjohn business and operates with global centers in the U.S., China and India.
Viatris (NASDAQ: VTRS) announced the appointment of Dr. Rogerio Vivaldi Coelho to its Board of Directors as part of its ongoing Board refreshment efforts. Dr. Vivaldi will join the reestablished Science and Technology Committee. He brings extensive experience from his previous roles, including CEO of Sigilon Therapeutics and executive positions at Bioverativ, Spark Therapeutics, and Genzyme. Viatris' Chair, Melina Higgins, and CEO, Scott A. Smith, expressed confidence in Dr. Vivaldi's ability to contribute significantly to the company's growth strategy and innovative pipeline. Dr. Vivaldi emphasized his alignment with Viatris' global vision and commitment to high-quality medicines.
Viatris (NASDAQ: VTRS), a global healthcare company, will participate in the Jeffries Global Healthcare Conference in New York on June 6, 2024. CEO Scott A. Smith and other executives will represent the company in a fireside chat at 8 a.m. ET.
Interested parties can access a live webcast and an archived version post-event at investor.viatris.com.
Viatris has released its 2023 Sustainability Report, emphasizing its commitment to sustainable access to medicine and community health. The report outlines efforts in four areas: Access and Global Health, Our People, Environment, and Community. Notably, the company sold over 80 billion doses of medicine across 165 countries and reached 90% of low- and lower-middle-income countries (LMICs). Initiatives include the Elevate wellbeing program for employees and a 3.7% reduction in greenhouse gas emissions since 2020. The report also highlights the documentary 'Empathy in Africa,' showcasing Viatris' support for healthcare in South Africa and the establishment of the Rhiza Babuyile Clinic. For more details, visit the company's sustainability report online.
Viatris reported strong first-quarter 2024 financial results, including total revenues of $3.66 billion, U.S. GAAP net earnings of $113.9 million, and adjusted EBITDA of $1.19 billion. The company also reaffirmed its 2024 financial guidance ranges and closed several significant transactions, such as the Idorsia transaction and Women's Healthcare Business divestiture. Additionally, Viatris returned $393 million of capital to shareholders in the form of dividends and share repurchases.
Viatris Inc. (NASDAQ: VTRS) will participate in the BofA Securities 2024 Health Care Conference in Las Vegas. CFO Doretta Mistras and CRO Philippe Martin will represent the company in a fireside chat. The event will be live webcasted on investor.viatris.com.
Viatris Inc. expands its global wellbeing program, Elevate, by launching Unmind, a mental health resource for colleagues. The program aims to support mental and physical health, foster community connections, and promote personal and professional growth. In response to rising rates of mental health issues, Viatris provides free mental health resources to all global colleagues. The partnership with Unmind underscores Viatris' commitment to destigmatizing mental health discussions in the workplace.
Summary not available.
Summary not available.
Summary not available.
Summary not available.